Interesting - can't say I understand why they chose that subset. I suppose it's possible that the hypermutated tumors have too wide a variety of neoantigens and so there will always be some tumor cells that are not covered by their vaccine.
It does appear to be the case that previously expressed neoantigens can disappear under selective pressure from treatment. So maybe they are going for tumors that are not too heterogeneous.
Market Data 
Markets 
